In the fall of 1999, a young chemical engineer named Todd Zion left his job at Eastman Kodak to enroll in the Ph.D. program at the Massachusetts Institute of Technology.
While looking for a subject to research, Zion noticed a grant proposal, never funded, that another graduate student had written on the subject of drug delivery. One possibility mentioned in the proposal was the development of a kind of insulin that would automatically respond to changes in blood-sugar levels, becoming active only when needed to maintain healthy levels around the clock. If it worked, the sugar-sensitive version could transform the lives of the six million people with diabetes in the United States who use insulin. No longer would they have to test their blood-sugar levels multiple times per day and try to calculate how much insulin to take. The self-regulating insulin would curtail high sugar levels, which raise the risk of long-term complications, and eradicate, or at least reduce, the most dangerous short-term complication: hypoglycemia, when sugar levels fall so low that they can cause confusion, unconsciousness, seizures and even death.
“I thought, Wow, that is a really neat area in which to do research,” Zion told me. Other researchers had been trying for 20 years to make insulin work only when needed. The first to publish a study were the scientists Michael Brownlee and Anthony Cerami, who in 1979 embedded a sugar-encrusted form of insulin in a mesh pouch with a sugar-loving protein called lectin. The idea was that when blood-sugar levels were elevated, the lectin would bind to the sugar in the blood and allow the insulin to leak out; when sugar levels were normal, the lectin would bind to the sugar-encrusted insulin, keeping it inside the pouch. But the system was impractical, because the pouch would need to be implanted under the skin and periodically refilled. And the lectin, derived from the jack-bean plant, was toxic.
In his first three years at M.I.T., Zion used nanoscale molecular engineering to create an insulin-lectin gel that could be injected without the need for an implanted pouch, while also rejiggering the lectin to make it less toxic. “It worked great visually,” he said. When the gel was placed in a sugar solution, “you could see the outer edge getting clear and dissolving . . . almost like an ice cube melting in water.”
The problem was that, no matter how hard he tried to manipulate the gel, the insulin either leaked out too easily, even when sugar levels were low, or not easily enough, when sugar levels were high.
Zion knew there was another approach: changing the insulin molecule itself, to make it sensitive to blood-sugar levels directly. But, he said, “almost everyone in the field of drug discovery believed that you should never, ever change the insulin molecule. . . . From a regulatory point of view, as soon as you manipulate the molecule, you’ve created a new drug. It doesn’t matter if you’ve attached a single atom to it.” Doing so, he knew, would require years of clinical trials in preparation for a new-drug application submission to the F.D.A. “That’s the only reason people were afraid.”
Zion’s trick was to attach a chemical arm — a short chain of sugars — directly onto the insulin molecule. (Attaching sugar to insulin? “Yes, it is a bit ironic,” he concedes.) The beauty of this approach is that it permits the insulin to latch directly onto the sugar-loving lectin in the gel — but only as needed. When blood-sugar levels are high, the lectin hooks up with any sugar floating freely from the blood, allowing the insulin molecule to do its normal job of connecting with insulin receptors on the surface of cells. (That is how insulin lowers blood-sugar levels, by merging with a cell’s insulin receptor and unlocking the cell membrane to allow sugar in.) When the sugar gets swallowed up by cells, lowering levels in the blood, the only remaining sweet for the lectin to attach to is the altered insulin’s sugar arm. Handcuffed to the lectin, the insulin can’t bind to insulin receptors. And so the insulin stops working to lower blood-sugar levels precisely when it’s no longer needed, because its sugar chain is held hostage by the lectin.
Zion called his new chemical creation smart insulin. In 2003, after testing it in rats, he won M.I.T.’s annual Entrepreneurship Competition. With the $30,000 prize money, he started a company called SmartCells and tried to see if he could make it work well enough to test it in humans.
The Latest on: Inventing drugs
via Google News
The Latest on: Inventing drugs
- Duke professor: Private sector plays key role in developing breakthrough medicineson November 20, 2019 at 1:38 pm
That's easier said than done. Pharmaceutical R&D is long and expensive, entailing high risks and variable outcomes. My own analysis finds that inventing and securing FDA approval for a new drug costs ...
- Axne doing right by Iowans on prescription drugs, despite misleading advertisements in Registeron November 20, 2019 at 1:21 pm
The price of a new invention usually falls as more people adopt it, but prescription drug prices somehow defy gravity. Iowans, like all Americans, pay among the highest drug prices in the world, and ...
- A new treatment promises to make little people taller. Is it an insult to ‘dwarf pride’?on November 20, 2019 at 2:47 am
Scientists have come up with a drug, injected once a day, that appears to make children’s bones grow. To many, it’s a wondrous invention that could improve the lives of thousands of people with ...
- Enochian Biosciences Is A House Of Cards - The Pipeline Is Entirely Pre-Clinical And Management Has A Questionable Historyon November 19, 2019 at 3:40 pm
Therefore, drugs in the pre-clinical stage are usually assigned zero value by public market ... Where did the newsletter get this information from? Clearly, Gumrukcu's invention of a hypothesis for an ...
- Ocean Beach residents say open drug use in the area has never been worseon November 18, 2019 at 5:53 pm
It’s been that way since the invention of the counter culture in the 1960s ... We wont be intimidated and won’t tolerate open drug use around the pier,” said OB Town Council President Mark Winkie.
- Pharmacovigilance and Drug Safety Software Market Is Expected To Witness Rapid Expansion By The End Of 2026on November 18, 2019 at 4:07 am
The market research report will also present an edifying overview of the competitive landscape of the Pharmacovigilance and Drug Safety Software market with a compilation of inventions, activities, ...
- Sinusitis Drugs Market Strategic Assessment by Top Players | Sanofi, Bayer, Pfizeron November 14, 2019 at 2:26 am
The sinusitis drugs market report provides a comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as revenue, investments and ...
- How Best To Use The Few New Drugs To Treat Antibiotic-Resistant Germs?on November 13, 2019 at 1:05 am
People in the business of inventing new drugs don't need to be told one of the most disturbing facts: It simply doesn't make much financial sense for companies to develop new antibiotics. The ...
- Who shrank the drug factory? Briefcase-sized labs could transform medicineon November 12, 2019 at 5:05 am
“These drugs have always been unaffordable for developing countries ... he has devoted himself to creating low-cost chemical sensors and using them and other homespun creations, to solve real-world ...
- Trump administration sues HIV prevention drug maker for patent infringementon November 7, 2019 at 4:35 am
Gilead responded in a statement on Thursday that the government patents are "invalid" and argued that Gilead deserves the credit for inventing the drugs. The company said it will ask the court to stay ...
via Bing News